Morningstar

VanEck Pharmaceutical ETF PPH

Morningstar Medalist Rating
Medalist Rating as of | See VanEck Investment Hub

Morningstar’s Analysis PPH

Will PPH outperform in the future?

Get our overall rating based on a fundamental assessment of the pillars below.

  • Process Pillar

    The Process Pillar is our assessment of how sensible, clearly defined, and repeatable PPH’s performance objective and investment process is for both security selection and portfolio construction.

  • People Pillar

    The People Pillar is our evaluation of the PPH management team’s experience and ability. We find that high-quality management teams deliver superior performance relative to their benchmarks and/or peers.

  • Parent Pillar

    The Parent Pillar is our rating of PPH’s parent organization’s priorities and whether they’re in line with investors’ interests.

null Morningstar Automated Analysis

Morningstar Automated Analysis

Summary

VanEck Pharmaceutical ETF holds a quantitatively derived Neutral Morningstar Medalist Rating. The rating suggests the model does not express a clear expectation of outperformance or underperformance relative to peers over a full market cycle.

by Morningstar Automated Analysis
Rated on Published on

Unlock our full analysis with Morningstar Investor

Portfolio Holdings PPH

More PPH Holdings
  • Current Portfolio Date
  • Equity Holdings —
  • Bond Holdings —
  • Other Holdings —
  • % Assets in Top 10 Holdings 72.0
Top 10 Holdings
% Portfolio Weight
Market Value USD
Sector

Eli Lilly and Co

21.87 236M
Healthcare

Merck & Co Inc

12.63 136M
Healthcare

Novo Nordisk AS ADR

5.45 59M
Healthcare

Pfizer Inc

5.15 56M
Healthcare

McKesson Corp

4.81 52M
Healthcare

Bristol-Myers Squibb Co

4.60 50M
Healthcare

Teva Pharmaceutical Industries Ltd

4.52 49M
Healthcare

GSK PLC ADR

4.46 48M
Healthcare

Cencora Inc

4.43 48M
Healthcare

Haleon PLC ADR

3.98 43M
Healthcare

Sponsor Center